Status:
COMPLETED
Real-life Observational Study of Cancer Pain Management With Methadone
Lead Sponsor:
RECORDATI GROUP
Conditions:
Cancer Pain
Eligibility:
All Genders
15+ years
Brief Summary
Study rational. Methadone is a distinctive opioid because of its pharmacological characteristics and its multiple modes of action, reinforcing its therapeutic value in managing advanced cancer pain, p...
Detailed Description
To describe the occurrence of overdose and QTc prolongation in patients initiating a treatment with Zoryon® for intractable cancer pain not adequately relieved from other level 3 opioids, from the day...
Eligibility Criteria
Inclusion
- Patients with intractable cancer pain inadequately relieved by other opioids (ineffective and/or excessive adverse events) AND for whom switching from opioid to Zoryon® has been prescribed.
- be aged 15 years or older;
- suffer from cancer pain;
- be treated with a level 3 opioid with inadequate pain relief, i.e., ineffective, excessive adverse effects, or both;
- have a prescription to initiate Zoryon® treatment.
Exclusion
- patients participating, or having participated within the previous month, in a clinical trial evaluating a new pain management treatment will be excluded, except for patients participating in the French experimentation of the use of therapeutical cannabis
Key Trial Info
Start Date :
February 21 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT05265442
Start Date
February 21 2022
End Date
December 31 2023
Last Update
October 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
LBR
Puteaux, France